Results 91 to 100 of about 35,949 (206)

Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidence

The Journal of Prevention of Alzheimer's Disease
Background: Safety profiles of lecanemab, an anti-amyloid-β antibody for the treatment of early Alzheimer’s disease (AD), remain uncertain and may vary between randomized controlled trials (RCTs) and real-world evidence (RWE) studies.
Lin Qi, Fangxue Zheng, Mengjiao Tu, Reema Abdullah, Yilei Zhao, Xinhui Su, Dan Zhou, Guoping Peng   +7 more
doaj   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

A prospective real‐world study of the efficacy and safety of aducanumab in China: Focus on early‐onset and autosomal dominant Alzheimer's disease

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Aducanumab is the first anti‐amyloid therapy used for Alzheimer's disease (AD) in China. METHODS This 12‐month, single‐center, real‐world study enrolled 12 participants with early AD receiving aducanumab 10 mg/kg every 4 weeks ...
Jinwen Xiao, Binyin Li, Biao Li, Jintao Wang, Ran Tang, Chao Gao, Xiangqian Che, Xiaomeng Xu, Shengdi Chen, Rujing Ren, Gang Wang   +10 more
doaj   +1 more source

Multi‐omics–driven precision medicine

iMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li, Zhe Zhao, Yifan Zhang, Yao Ma, Gaofei Hu, Min Zeng, Zhanqun Yang, Zixuan Zhao, Xin Zhou, Wei Hu, Yuxuan Sun, Meng Su, Jun Li, Matthew Whiteman, Wei Fu, Chao Zhong, Lemin Zheng, Long Chen, Hairong Lv, Rongsheng Zhao, Yi Zhun Zhu   +20 more
wiley   +1 more source

Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist

Journal of the Korean Society of Radiology
Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval, and subsequently, lecanemab has been approved by the Korean FDA and it has recently entered commercial use in Korea.
So Yeong Jeong, Chong Hyun Suh, Jae-Sung Lim, Yangsean Choi, Ho Sung Kim, Sang Joon Kim, Jae-Hong Lee   +6 more
doaj   +1 more source

Clustering of Cerebral Microbleeds in Cerebral Amyloid Angiopathy: A Flow Territory‐Based Analysis

Journal of Magnetic Resonance Imaging, EarlyView.
ABSTRACT Background Cerebral microbleeds (CMBs) are a key imaging marker of cerebral amyloid angiopathy (CAA), but their individual spatial distribution and potential clustering remain poorly understood. Purpose This study assessed whether CMBs exhibit patient‐specific, flow territory‐based clustering in sporadic (sCAA) and Dutch‐type hereditary CAA (D‐
Manon R. Schipper, Reinier G. J. van der Zwet, Jelle J. Goeman, Thijs W. van Harten, Emma A. Koemans, Marieke J. H. Wermer, Marianne A. A. van Walderveen, Matthias J. P. van Osch   +7 more
wiley   +1 more source

Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease

Journal of Alzheimer's Disease Reports
Lecanemab has demonstrated amyloid reduction and slowed clinical decline in early Alzheimer's disease trials. Herein, we report retrospective case series results on lecanemab treatment in our clinic. Overall, 61 individuals were included.
Alyanna Ferrer, Justin Moon
doaj   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Proteoforms in Disease: Biomedical Applications of Top‐Down Proteomics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The proteome is a dynamic landscape of proteoforms arising from genetic mutations, alternative splicing, and post‐translational modifications (PTMs), which collectively drive biological function and disease phenotypes. Mass spectrometry (MS)‐based proteomics has emerged as an essential technique for elucidating this molecular complexity ...
Holden T. Rogers, Zachery R. Gregorich, Megan S. Gant, Zhan Gao, Julia Chamot‐Rooke, Ying Ge   +5 more
wiley   +1 more source

Multiomics Insights Into AL Amyloidosis

Medicine Bulletin, EarlyView.
ABSTRACT Light chain amyloidosis is a systemic or localized protein conformational disorder triggered by misfolded immunoglobulin light chains, leading to amyloid fibril deposition. The disease is characterized by multiorgan involvement and delayed diagnosis, contributing to poor prognosis and high mortality rates.
Zixuan Zhang, Ziru Huang, Haoxiang Tang, Xianrun Pan, Rong Wang, Dingding Zhang, Jian Huang   +6 more
wiley   +1 more source